BPS 2023
Enhanced Delivery Oligonucleotide Platform for Neuromuscular Diseases
Geeta Meher
Associate Director, Discovery Chemistry, PepGen
ABSTRACT
PepGen Inc. is a clinical-stage biotechnology company, advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
BIO
Geeta Meher was born in Uttar Pradesh, India. She completed her undergraduate degrees with majors in Chemistry and Mathematics from Udai Pratap College, Varanasi, India. Further, she finished my Masters in Organic Chemistry from Banaras Hindu University, India. She completed her PhD from University of Florida in Organic Chemistry in 2009, and pursued Postdoctoral Research at The Scripps Research Institute, La Jolla, California and at University of California, Davis for one year. In Sept 2015, she joined Spring Bank Pharmaceuticals, Milford, MA as a Research Scientist and worked there for approximately 5 years on Small Molecules Nucleic Acid Hybrids, oligonucleotides, and bioconjugates. In approximately 3 years, she was promoted to Principal Scientist, and played a critical role in the development of SB11285. In Nov 2020, she joined Stoke Therapeutics, Bedford, MA as principal Scientist in Oligonucleotide Chemistry. In Aug 2022, she joined as Associate Director in Discovery Chemistry at PepGen Inc, Boston, MA. Her current role focuses on continued development of enhanced delivery oligonucleotide (EDO) for neuromuscular diseases and expanding our pipeline to other indications towards broadening our EDO technology.